<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://gut.bmj.com">
<title>Gut current issue</title>
<link>http://gut.bmj.com</link>
<description>Gut RSS feed -- current issue</description>
<prism:coverDisplayDate>Jun  1 2013 12:00:00:000AM</prism:coverDisplayDate>
<prism:publicationName>Gut</prism:publicationName>
<prism:issn>0017-5749</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://gut.bmj.com/cgi/content/short/62/6/i?rss=1" />
  <rdf:li rdf:resource="http://gut.bmj.com/cgi/content/short/62/6/803?rss=1" />
  <rdf:li rdf:resource="http://gut.bmj.com/cgi/content/short/62/6/808?rss=1" />
  <rdf:li rdf:resource="http://gut.bmj.com/cgi/content/short/62/6/810?rss=1" />
  <rdf:li rdf:resource="http://gut.bmj.com/cgi/content/short/62/6/812?rss=1" />
  <rdf:li rdf:resource="http://gut.bmj.com/cgi/content/short/62/6/824?rss=1" />
  <rdf:li rdf:resource="http://gut.bmj.com/cgi/content/short/62/6/833?rss=1" />
  <rdf:li rdf:resource="http://gut.bmj.com/cgi/content/short/62/6/842?rss=1" />
  <rdf:li rdf:resource="http://gut.bmj.com/cgi/content/short/62/6/851?rss=1" />
  <rdf:li rdf:resource="http://gut.bmj.com/cgi/content/short/62/6/852?rss=1" />
  <rdf:li rdf:resource="http://gut.bmj.com/cgi/content/short/62/6/863?rss=1" />
  <rdf:li rdf:resource="http://gut.bmj.com/cgi/content/short/62/6/871?rss=1" />
  <rdf:li rdf:resource="http://gut.bmj.com/cgi/content/short/62/6/882?rss=1" />
  <rdf:li rdf:resource="http://gut.bmj.com/cgi/content/short/62/6/890?rss=1" />
  <rdf:li rdf:resource="http://gut.bmj.com/cgi/content/short/62/6/899?rss=1" />
  <rdf:li rdf:resource="http://gut.bmj.com/cgi/content/short/62/6/911?rss=1" />
  <rdf:li rdf:resource="http://gut.bmj.com/cgi/content/short/62/6/920?rss=1" />
  <rdf:li rdf:resource="http://gut.bmj.com/cgi/content/short/62/6/933?rss=1" />
  <rdf:li rdf:resource="http://gut.bmj.com/cgi/content/short/62/6/948?rss=1" />
  <rdf:li rdf:resource="http://gut.bmj.com/cgi/content/short/62/6/950?rss=1" />
  <rdf:li rdf:resource="http://gut.bmj.com/cgi/content/short/62/6/950-a?rss=1" />
  <rdf:li rdf:resource="http://gut.bmj.com/cgi/content/short/62/6/951?rss=1" />
  <rdf:li rdf:resource="http://gut.bmj.com/cgi/content/short/62/6/952?rss=1" />
  <rdf:li rdf:resource="http://gut.bmj.com/cgi/content/short/62/6/952-a?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://hwmaint.gut.bmj.com/homepage/GUT_95x60.gif" />
</channel>
<image rdf:about="http://hwmaint.gut.bmj.com/homepage/GUT_95x60.gif">
<title>Gut</title>
<url>http://hwmaint.gut.bmj.com/homepage/GUT_95x60.gif</url>
<link>http://gut.bmj.com</link>
</image>
<item rdf:about="http://gut.bmj.com/cgi/content/short/62/6/i?rss=1">
<title><![CDATA[Highlights from this issue]]></title>
<link>http://gut.bmj.com/cgi/content/short/62/6/i?rss=1</link>
<description><![CDATA[ <sec id="s1"><st></st><sec id="s1a"><st>Luminal GI</st><sec id="s1a1"><st>Omeprazole's eosinophil-reducing properties</st> <p>Eosinophilic oesophagitis (EoE) and gastro-oesophageal reflux disease (GORD) share clinical and histological features and it is sometimes difficult to distinguish the two disorders, though some reports suggest that response to PPIs might be a useful test. The premise is that reduced gastric acid secretion is the only important effect of PPIs and, therefore, only an acid-peptic disorder like GORD can respond to PPIs. It is also known that oesophageal expression of eotaxin-3 stimulated by Th2 cytokines might contribute to oesophageal eosinophilia in EoE while Th2 cytokine effects on the oesophagus in GORD are not known. In this issue of Gut, Cheng et al measured eotaxin-3 protein secretion stimulated by Th2 cytokines (interleukin (IL)-4 and IL-13) in telomerase-immortalised and primary cultures of oesophageal squamous cells from GORD and EoE patients. Oesophageal squamous cells from GORD and EoE patients expressed similar levels of eotaxin-3...]]></description>
<dc:creator><![CDATA[El-Omar, E., Grady, W., Gerbes, A.]]></dc:creator>
<dc:date>2013-04-30T00:24:20-07:00</dc:date>
<dc:identifier>info:doi/10.1136/gutjnl-2013-305078</dc:identifier>
<dc:identifier>hwp:master-id:gutjnl;gutjnl-2013-305078</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[Highlights from this issue]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Digest</prism:section>
<prism:volume>62</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>i</prism:startingPage>
<prism:endingPage>ii</prism:endingPage>
</item>
<item rdf:about="http://gut.bmj.com/cgi/content/short/62/6/803?rss=1">
<title><![CDATA[Biosimilars in IBD: hope or expectation?]]></title>
<link>http://gut.bmj.com/cgi/content/short/62/6/803?rss=1</link>
<description><![CDATA[ <sec id="s1"><st>Introduction</st> <p>A biosimilar is a biological medicine that enters the market subsequent to expiration of the patent of an original reference product and its similarity to the reference medicine exhibits &lsquo;no clinically meaningful differences in terms of quality, safety and efficacy&rsquo;.<cross-ref type="bib" refid="R1">1</cross-ref> In practice, patents protect a reference product for 10&nbsp;years after its approval before registration for a similar biological medicine can be applied for.<cross-ref type="bib" refid="R1">1</cross-ref> The term &lsquo;biosimilar&rsquo; is recognised by all regulators, but synonyms include &lsquo;similar biotherapeutic product&rsquo; (WHO) and &lsquo;subsequent-entry biologic&rsquo; (Canada).<cross-ref type="bib" refid="R2">2</cross-ref> Biopharmaceutical agents are derived from living cells or organisms and are usually complex proteins. Therefore, regulators are establishing novel specific approval pathways for biosimilars that differ from those for chemical generics. Since the first approval in 2005, several biosimilars of somatropin (human growth hormone), filgrastim (granulocyte colony-stimulating factor, G-CSF) and epoetin (erythropoietin) have become available in Europe. Currently, 12...]]></description>
<dc:creator><![CDATA[Gecse, K. B., Khanna, R., van den Brink, G. R., Ponsioen, C. Y., Lowenberg, M., Jairath, V., Travis, S. P. L., Sandborn, W. J., Feagan, B. G., D'Haens, G. R. A. M.]]></dc:creator>
<dc:date>2013-04-30T00:24:20-07:00</dc:date>
<dc:identifier>info:doi/10.1136/gutjnl-2012-303824</dc:identifier>
<dc:identifier>hwp:master-id:gutjnl;gutjnl-2012-303824</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Crohn's disease]]></dc:subject>
<dc:title><![CDATA[Biosimilars in IBD: hope or expectation?]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Leading article</prism:section>
<prism:volume>62</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>803</prism:startingPage>
<prism:endingPage>807</prism:endingPage>
</item>
<item rdf:about="http://gut.bmj.com/cgi/content/short/62/6/808?rss=1">
<title><![CDATA[A novel genetic marker of liver disease aetiology in hepatocellular carcinoma: culling the metabolic syndrome]]></title>
<link>http://gut.bmj.com/cgi/content/short/62/6/808?rss=1</link>
<description><![CDATA[ <p>Paradis <I>et al</I><cross-ref type="bib" refid="R1">1</cross-ref> describe the work in which they identified <I>CUL7</I> as a unique target gene in metabolic syndrome-related hepatocellular carcinoma (HCC). The increased worldwide prevalence and incidence of liver disease related to metabolic syndrome<cross-ref type="bib" refid="R2">2</cross-ref> are noted as factors in the changing epidemiology and demographics of HCC, especially in otherwise &lsquo;low-risk&rsquo; regions.<cross-ref type="bib" refid="R3">3&ndash;5</cross-ref><cross-ref type="bib" refid="R4"></cross-ref><cross-ref type="bib" refid="R5"></cross-ref> Although this highly lethal malignancy remains most commonly associated with underlying cirrhosis secondary to viral hepatitis C or B,<cross-ref type="bib" refid="R6">6</cross-ref> <cross-ref type="bib" refid="R7">7</cross-ref> or alcohol,<cross-ref type="bib" refid="R7">7</cross-ref> there is growing acceptance of the role of non-alcoholic steatohepatitis as another chronic liver disease that may predispose to the subsequent genetic and molecular aberrations that result in malignancy. Furthermore, investigators are showing the existence of an alarming trend in the evolution of HCC in the presence of metabolic syndrome before advanced fibrosis or cirrhosis.<cross-ref type="bib" refid="R3">3</cross-ref> <cross-ref type="bib"...]]></description>
<dc:creator><![CDATA[Brunt, E. M.]]></dc:creator>
<dc:date>2013-04-30T00:24:20-07:00</dc:date>
<dc:identifier>info:doi/10.1136/gutjnl-2012-303451</dc:identifier>
<dc:identifier>hwp:master-id:gutjnl;gutjnl-2012-303451</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[A novel genetic marker of liver disease aetiology in hepatocellular carcinoma: culling the metabolic syndrome]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Commentary</prism:section>
<prism:volume>62</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>808</prism:startingPage>
<prism:endingPage>809</prism:endingPage>
</item>
<item rdf:about="http://gut.bmj.com/cgi/content/short/62/6/810?rss=1">
<title><![CDATA[Exercise-induced SPARC prevents tumorigenesis of colon cancer]]></title>
<link>http://gut.bmj.com/cgi/content/short/62/6/810?rss=1</link>
<description><![CDATA[ <p>Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in North America and Europe. Happily, the incidence and mortality of CRC have declined by 3.4% and 3.0%, respectively, from 2003 to 2007 in the USA.<cross-ref type="bib" refid="R1">1</cross-ref> The decline in incidence is attributed to the public health emphasis on the importance of CRC screening and the reduction of behavioural risk factors. For the majority of people who do not use tobacco and alcohol, the most important determinants of CRC risk factors are weight control, dietary choice and level of physical activity. A number of investigations have demonstrated the benefit of exercise on CRC prevention, and guidelines released by governmental and non-governmental organisations also emphasise the importance of regular exercise for decreasing CRC incidence.</p> <p>Although the correlation between exercise and CRC prevention is conclusive, the molecular mechanism for the protective effect of exercise remains largely unresolved. Epidemiological and...]]></description>
<dc:creator><![CDATA[Liu, Y.-P., Hsiao, M.]]></dc:creator>
<dc:date>2013-04-30T00:24:20-07:00</dc:date>
<dc:identifier>info:doi/10.1136/gutjnl-2012-303235</dc:identifier>
<dc:identifier>hwp:master-id:gutjnl;gutjnl-2012-303235</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[Exercise-induced SPARC prevents tumorigenesis of colon cancer]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Commentary</prism:section>
<prism:volume>62</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>810</prism:startingPage>
<prism:endingPage>811</prism:endingPage>
</item>
<item rdf:about="http://gut.bmj.com/cgi/content/short/62/6/812?rss=1">
<title><![CDATA[Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts]]></title>
<link>http://gut.bmj.com/cgi/content/short/62/6/812?rss=1</link>
<description><![CDATA[
<p>Lynch syndrome (LS) is characterised by the development of colorectal cancer, endometrial cancer and various other cancers, and is caused by a mutation in one of the mismatch repair genes: <I>MLH1, MSH2, MSH6</I> or <I>PMS2</I>. In 2007, a group of European experts (the Mallorca group) published guidelines for the clinical management of LS. Since then substantial new information has become available necessitating an update of the guidelines. In 2011 and 2012 workshops were organised in Palma de Mallorca. A total of 35 specialists from 13 countries participated in the meetings. The first step was to formulate important clinical questions. Then a systematic literature search was performed using the Pubmed database and manual searches of relevant articles. During the workshops the outcome of the literature search was discussed in detail. The guidelines described in this paper may be helpful for the appropriate management of families with LS. Prospective controlled studies should be undertaken to improve further the care of these families.</p>
]]></description>
<dc:creator><![CDATA[Vasen, H. F. A., Blanco, I., Aktan-Collan, K., Gopie, J. P., Alonso, A., Aretz, S., Bernstein, I., Bertario, L., Burn, J., Capella, G., Colas, C., Engel, C., Frayling, I. M., Genuardi, M., Heinimann, K., Hes, F. J., Hodgson, S. V., Karagiannis, J. A., Lalloo, F., Lindblom, A., Mecklin, J.-P., Moller, P., Myrhoj, T., Nagengast, F. M., Parc, Y., Ponz de Leon, M., Renkonen-Sinisalo, L., Sampson, J. R., Stormorken, A., Sijmons, R. H., Tejpar, S., Thomas, H. J. W., Rahner, N., Wijnen, J. T., Jarvinen, H. J., Moslein, G., (the Mallorca group)]]></dc:creator>
<dc:date>2013-04-30T00:24:20-07:00</dc:date>
<dc:identifier>info:doi/10.1136/gutjnl-2012-304356</dc:identifier>
<dc:identifier>hwp:master-id:gutjnl;gutjnl-2012-304356</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Open access, Editor's choice, Colon cancer]]></dc:subject>
<dc:title><![CDATA[Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Guidelines</prism:section>
<prism:volume>62</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>812</prism:startingPage>
<prism:endingPage>823</prism:endingPage>
</item>
<item rdf:about="http://gut.bmj.com/cgi/content/short/62/6/824?rss=1">
<title><![CDATA[Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD]]></title>
<link>http://gut.bmj.com/cgi/content/short/62/6/824?rss=1</link>
<description><![CDATA[
<sec><st>Objective</st>
<p>Eosinophilic oesophagitis (EoE) and gastro-oesophageal reflux disease (GORD) can have similar clinical and histological features. Proton pump inhibitors (PPIs) are used to distinguish the disorders, with the assumption that only GORD can respond to PPIs. Oesophageal expression of eotaxin-3 stimulated by Th2 cytokines might contribute to oesophageal eosinophilia in EoE. Th2 cytokine effects on the oesophagus in GORD are not known. The objective of the authors was to explore the molecular mechanisms of Th2 cytokines on eotaxin-3 expression by oesophageal squamous cells from patients with GORD and EoE, and the effects of omeprazole on that eotaxin-3 expression.</p>
</sec>
<sec><st>Design</st>
<p>Using telomerase-immortalised and primary cultures of oesophageal squamous cells from GORD and EoE patients, the authors measured eotaxin-3 protein secretion stimulated by Th2 cytokines (interleukin (IL)-4 and IL-13). Eotaxin-3 promoter constructs were used to study transcriptional regulation. Cytokine-induced eotaxin-3 mRNA and protein expression were measured in the presence or absence of omeprazole.</p>
</sec>
<sec><st>Results</st>
<p>There were no significant differences between EoE and GORD primary cells in cytokine-stimulated eotaxin-3 protein secretion levels. In EoE and GORD cell lines, IL-4 and IL-13 activated the eotaxin-3 promoter, and significantly increased eotaxin-3 mRNA and protein expression. Omeprazole blocked the cytokine-stimulated increase in eotaxin-3 mRNA and protein expression in EoE and GORD cell lines.</p>
</sec>
<sec><st>Conclusion</st>
<p>Oesophageal squamous cells from GORD and EoE patients express similar levels of eotaxin-3 when stimulated by Th2 cytokines, and omeprazole blocks that eotaxin-3 expression. These findings suggest that PPIs might have eosinophil-reducing effects independent of effects on acid reflux and that response to PPIs might not distinguish EoE from GORD.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Cheng, E., Zhang, X., Huo, X., Yu, C., Zhang, Q., Wang, D. H., Spechler, S. J., Souza, R. F.]]></dc:creator>
<dc:date>2013-04-30T00:24:20-07:00</dc:date>
<dc:identifier>info:doi/10.1136/gutjnl-2012-302250</dc:identifier>
<dc:identifier>hwp:master-id:gutjnl;gutjnl-2012-302250</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Gastro-oesophageal reflux]]></dc:subject>
<dc:title><![CDATA[Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Oesophagus</prism:section>
<prism:volume>62</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>824</prism:startingPage>
<prism:endingPage>832</prism:endingPage>
</item>
<item rdf:about="http://gut.bmj.com/cgi/content/short/62/6/833?rss=1">
<title><![CDATA[Zinc-finger protein 545 is a novel tumour suppressor that acts by inhibiting ribosomal RNA transcription in gastric cancer]]></title>
<link>http://gut.bmj.com/cgi/content/short/62/6/833?rss=1</link>
<description><![CDATA[
<sec><st>Objective</st>
<p>Zinc-finger protein 545 (ZNF545) is a member of the family of Kr&uuml;ppel-associated box-containing zinc-finger proteins. The aim of this study was to clarify its biological function as a tumour suppressor in gastric cancer.</p>
</sec>
<sec><st>Design</st>
<p>The biological function of ZNF545 was determined by cell growth and apoptosis assays. The ZNF545 target signal pathway was identified by promoter luciferase assay, northern blot, run-on transcription assay, chromatin immunoprecipitation and coimmunoprecipitation assays. The clinical application of ZNF545 was assessed in primary gastric cancers.</p>
</sec>
<sec><st>Results</st>
<p>ZNF545 was silenced or reduced in 16 out of 18 gastric cancer cell lines by promoter hypermethylation. Restoration of ZNF545 expression in gastric cancer cell lines suppressed cell proliferation and induced apoptosis. These effects of ZNF545 were attributed to inhibition of ribosomal RNA (rRNA) transcription. Inhibition of rRNA transcription by ZNF545 was further revealed to be associated with direct ribosomal DNA (rDNA) promoter binding, recruitment of the corepressor, heterochromatin protein 1&beta;, and reduction of trimethylated histone H3 at the Lys4 residue at the rDNA locus. ZNF545 methylation was detected in 51.9% (41/79) of gastric cancer tissues, 27.0% (20/74) of adjacent non-tumour gastric tissues (p=0.001), but none of 20 normal controls. Multivariate analysis revealed that patients with ZNF545 methylation had a significant decrease in overall survival. Kaplan&ndash;Meier survival curves showed that ZNF545 methylation was significantly associated with shortened survival in patients with stage I&ndash;II gastric cancer.</p>
</sec>
<sec><st>Conclusions</st>
<p>ZNF545 acts as a functional tumour suppressor in gastric cancer by inhibiting rRNA transcription. Its methylation at early stages of gastric carcinogenesis is an independent prognostic factor.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Wang, S., Cheng, Y., Du, W., Lu, L., Zhou, L., Wang, H., Kang, W., Li, X., Tao, Q., Sung, J. J. Y., Yu, J.]]></dc:creator>
<dc:date>2013-04-30T00:24:20-07:00</dc:date>
<dc:identifier>info:doi/10.1136/gutjnl-2011-301776</dc:identifier>
<dc:identifier>hwp:master-id:gutjnl;gutjnl-2011-301776</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Pancreatic cancer]]></dc:subject>
<dc:title><![CDATA[Zinc-finger protein 545 is a novel tumour suppressor that acts by inhibiting ribosomal RNA transcription in gastric cancer]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Stomach</prism:section>
<prism:volume>62</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>833</prism:startingPage>
<prism:endingPage>841</prism:endingPage>
</item>
<item rdf:about="http://gut.bmj.com/cgi/content/short/62/6/842?rss=1">
<title><![CDATA[Weaning diet induces sustained metabolic phenotype shift in the pig and influences host response to Bifidobacterium lactis NCC2818]]></title>
<link>http://gut.bmj.com/cgi/content/short/62/6/842?rss=1</link>
<description><![CDATA[
<sec><st>Background</st>
<p>The process of weaning causes a major shift in intestinal microbiota and is a critical period for developing appropriate immune responses in young mammals.</p>
</sec>
<sec><st>Objective</st>
<p>To use a new systems approach to provide an overview of host metabolism and the developing immune system in response to nutritional intervention around the weaning period.</p>
</sec>
<sec><st>Design</st>
<p>Piglets (n=14) were weaned onto either an egg-based or soya-based diet at 3&nbsp;weeks until 7&nbsp;weeks, when all piglets were switched onto a fish-based diet. Half the animals on each weaning diet received <I>Bifidobacterium lactis</I> NCC2818 supplementation from weaning onwards. Immunoglobulin production from immunologically relevant intestinal sites was quantified and the urinary <sup>1</sup>H NMR metabolic profile was obtained from each animal at post mortem (11&nbsp;weeks).</p>
</sec>
<sec><st>Results</st>
<p>Different weaning diets induced divergent and sustained shifts in the metabolic phenotype, which resulted in the alteration of urinary gut microbial co-metabolites, even after 4&nbsp;weeks of dietary standardisation. <I>B lactis</I> NCC2818 supplementation affected the systemic metabolism of the different weaning diet groups over and above the effects of diet. Additionally, production of gut mucosa-associated IgA and IgM was found to depend upon the weaning diet and on <I>B lactis</I> NCC2818 supplementation.</p>
</sec>
<sec><st>Conclusion</st>
<p>The correlation of urinary <sup>1</sup>H NMR metabolic profile with mucosal immunoglobulin production was demonstrated, thus confirming the value of this multi-platform approach in uncovering non-invasive biomarkers of immunity. This has clear potential for translation into human healthcare with the development of urine testing as a means of assessing mucosal immune status. This might lead to early diagnosis of intestinal dysbiosis and with subsequent intervention, arrest disease development. This system enhances our overall understanding of pathologies under supra-organismal control.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Merrifield, C. A., Lewis, M. C., Claus, S. P., Pearce, J. T. M., Cloarec, O., Duncker, S., Heinzmann, S. S., Dumas, M.-E., Kochhar, S., Rezzi, S., Mercenier, A., Nicholson, J. K., Bailey, M., Holmes, E.]]></dc:creator>
<dc:date>2013-04-30T00:24:21-07:00</dc:date>
<dc:identifier>info:doi/10.1136/gutjnl-2011-301656</dc:identifier>
<dc:identifier>hwp:master-id:gutjnl;gutjnl-2011-301656</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[Weaning diet induces sustained metabolic phenotype shift in the pig and influences host response to Bifidobacterium lactis NCC2818]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Gut microbiota</prism:section>
<prism:volume>62</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>842</prism:startingPage>
<prism:endingPage>851</prism:endingPage>
</item>
<item rdf:about="http://gut.bmj.com/cgi/content/short/62/6/851?rss=1">
<title><![CDATA[When dermatology meets gastroenterology: a case of odynophagia]]></title>
<link>http://gut.bmj.com/cgi/content/short/62/6/851?rss=1</link>
<description><![CDATA[ <sec><st>Clinical presentation</st> <p>A 60-year-old woman with a long standing history of cutaneous pemphigus vulgaris (PV), was admitted to our hospital complaining of progressive dysphagia and odynophagia to both liquids and solids over a 2-month duration. Patient suffered from limited oral caloric intake and a 30-pound weight loss. Current medication included oral Prednisone and recently started Azathioprine. On physical examination, she had multiple denuded hyperaemic lesions involving soft palate, gingiva, uvula, and oropharynx. Numerous hyperpigmented cutaneous macules and crusted erosions in different stages of healing were appreciated, however, no skin bullae were seen. Upper endoscopy confirmed oral and pharyngeal findings and showed several friable zigzagging superficial ulcerations in the proximal and mid-oesophagus (<cross-ref type="fig" refid="fig1">figure 1A</cross-ref>) with easy exfoliation of the mucosa on gentle passage of the gastroscope (<cross-ref type="fig" refid="fig1">figure 1B</cross-ref>).</p> </sec> <sec><st>Question</st> <p>What is the diagnosis?</p> <p><I>See page below for answer</I></p> </sec> <sec><st>Answer</st> <p><I>From question on page above</I></p>...]]></description>
<dc:creator><![CDATA[Gurvits, G. E.]]></dc:creator>
<dc:date>2013-04-30T00:24:21-07:00</dc:date>
<dc:identifier>info:doi/10.1136/gutjnl-2012-303217</dc:identifier>
<dc:identifier>hwp:master-id:gutjnl;gutjnl-2012-303217</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[GUT Snapshot]]></dc:subject>
<dc:title><![CDATA[When dermatology meets gastroenterology: a case of odynophagia]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Editor&#x27;s quiz: GI snapshot</prism:section>
<prism:volume>62</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>851</prism:startingPage>
<prism:endingPage>851</prism:endingPage>
</item>
<item rdf:about="http://gut.bmj.com/cgi/content/short/62/6/852?rss=1">
<title><![CDATA[Adipokines from local fat cells shape the macrophage compartment of the creeping fat in Crohn's disease]]></title>
<link>http://gut.bmj.com/cgi/content/short/62/6/852?rss=1</link>
<description><![CDATA[
<sec><st>Objective</st>
<p>The creeping fat in Crohn's disease (CD) is infiltrated by macrophages; local adipokine levels are increased. This study aimed to link these observations to define a role for macrophages in the pathology of human CD.</p>
</sec>
<sec><st>Methods</st>
<p>Human peripheral blood CD14 cells were polarised in vitro into M1 and M2 macrophages. The effects on adipokine receptors, phenotypic surface markers, cytokines and chemokines were assessed after treatment with leptin and adiponectin. Immunohistochemistry visualised macrophage subtypes in samples of mesenteric fat tissue from patients with CD. The chemotactic potential of secreted macrophage products was determined by T cell migration and chemokine production in vitro.</p>
</sec>
<sec><st>Results</st>
<p>Although both adipokines altered the phenotype and function of M1 and M2 macrophages, M2 macrophages were more susceptible. M1 responded to leptin by increased cytokine production, but the stronger effect was seen in M2 macrophages with high expression of interleukin (IL)-10, IL-6 and tumour necrosis factor &alpha;. Adiponectin exerted similar effects and led to upregulated mannose receptor expression by M2 macrophages. Large macrophage numbers within the mesenteric fat tissue of patients with CD comprise a unique infiltration predominantly of M2 macrophages, leading to an IL-10-rich environment. While leptin increased the potency of both subtypes to attract CD3 T cells, adiponectin only affected M2 macrophages.</p>
</sec>
<sec><st>Conclusion</st>
<p>The adipocyte-dependent microenvironment within the creeping fat of patients with CD modulates the local macrophage compartment to a preference for the M2 subtype. The findings in this study with human cells suggest a protective role for the mesenteric fat in CD in terms of an enveloping barrier with the potential to limit intestinal inflammation.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Kredel, L. I., Batra, A., Stroh, T., Kuhl, A. A., Zeitz, M., Erben, U., Siegmund, B.]]></dc:creator>
<dc:date>2013-04-30T00:24:21-07:00</dc:date>
<dc:identifier>info:doi/10.1136/gutjnl-2011-301424</dc:identifier>
<dc:identifier>hwp:master-id:gutjnl;gutjnl-2011-301424</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Crohn's disease]]></dc:subject>
<dc:title><![CDATA[Adipokines from local fat cells shape the macrophage compartment of the creeping fat in Crohn's disease]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Inflammatory bowel disease</prism:section>
<prism:volume>62</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>852</prism:startingPage>
<prism:endingPage>862</prism:endingPage>
</item>
<item rdf:about="http://gut.bmj.com/cgi/content/short/62/6/863?rss=1">
<title><![CDATA[Risk factors for advanced neoplasia within subcentimetric polyps: implications for diagnostic imaging]]></title>
<link>http://gut.bmj.com/cgi/content/short/62/6/863?rss=1</link>
<description><![CDATA[
<sec><st>Objective</st>
<p>Diagnostic imaging by CT colonography and capsule endoscopy is used to detect colonic lesions. Controversy exists regarding the work-up of subcentimetric lesions. The aim of this study was to identify risk indicators for advanced neoplasia (AN) in subcentimetric polyps.</p>
</sec>
<sec><st>Design</st>
<p>Colonoscopies were classified on the basis of the largest lesion found. AN was defined as high-grade dysplasia, villous histology, or cancer. Logistic regression models were developed to identify risk factors for AN, and validated on separate datasets. A risk index based on the logistic regression was generated, and the number needed to screen (NNS) to detect AN was determined.</p>
</sec>
<sec><st>Results</st>
<p>1 077 956 colonoscopies identified 106 270 intermediate (5&ndash;9 mm) and 198 954 diminutive (&le;4 mm) lesions; 13% of intermediate and 3.7% of diminutive lesions contained AN. The risk of AN was higher in intermediate than in diminutive lesions (OR 3.1; 95% CI 3.0 to 3.3). Age &ge;85 versus &lt;45&nbsp;years was associated with ORs of 2.4 (95% CI 1.8 to 3.1) for intermediate polyps and 3.2 (95% CI 2.3 to 4.5) for diminutive polyps. Pedunculated versus sessile morphology was associated with a higher risk of AN in intermediate (OR 2.0; 95% CI 1.9 to 2.2) and diminutive (OR 3.5; 95% CI 2.9 to 4.1) lesions. In the combined analysis for subcentimetric lesions, ORs were 2.7 (95% CI 2.2 to 3.3) for age &ge;85 versus &lt;45&nbsp;years, 1.1 (95% CI 1.1 to 1.2) for male sex, 1.6 (95% CI 1.4 to 1.7) for occult blood, 1.3 (95% CI 1.2 to 1.5) for overt blood in stool, 1.3 (95% CI 1.2 to 1.4) for more than four lesions, and 2.2 (95% CI 2.1 to 2.3) for pedunculated versus sessile lesions. At median risk index values, the NNS was 9.3 (95% CI 9.1 to 9.5) in individuals with intermediate lesions and 29.4 (95% CI 28.5 to 30.2) in those with diminutive lesions. Compared with the NNS of 15 of the whole cohort, the majority of intermediate, but a minority of diminutive, lesions were deemed at high risk of AN.</p>
</sec>
<sec><st>Conclusion</st>
<p>This study successfully identified risk factors and established a risk index for subcentimetric lesions. This has implications for the work-up of patients with subcentimetric lesions identified on diagnostic imaging.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Kolligs, F. T., Crispin, A., Graser, A., Munte, A., Mansmann, U., Goke, B.]]></dc:creator>
<dc:date>2013-04-30T00:24:21-07:00</dc:date>
<dc:identifier>info:doi/10.1136/gutjnl-2011-300111</dc:identifier>
<dc:identifier>hwp:master-id:gutjnl;gutjnl-2011-300111</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Endoscopy, Colon cancer]]></dc:subject>
<dc:title><![CDATA[Risk factors for advanced neoplasia within subcentimetric polyps: implications for diagnostic imaging]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Colon</prism:section>
<prism:volume>62</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>863</prism:startingPage>
<prism:endingPage>870</prism:endingPage>
</item>
<item rdf:about="http://gut.bmj.com/cgi/content/short/62/6/871?rss=1">
<title><![CDATA[Cumulative impact of common genetic variants and other risk factors on colorectal cancer risk in 42 103 individuals]]></title>
<link>http://gut.bmj.com/cgi/content/short/62/6/871?rss=1</link>
<description><![CDATA[
<sec><st>Objective</st>
<p>Colorectal cancer (CRC) has a substantial heritable component. Common genetic variation has been shown to contribute to CRC risk. A study was conducted in a large multi-population study to assess the feasibility of CRC risk prediction using common genetic variant data combined with other risk factors. A risk prediction model was built and applied to the Scottish population using available data.</p>
</sec>
<sec><st>Design</st>
<p>Nine populations of European descent were studied to develop and validate CRC risk prediction models. Binary logistic regression was used to assess the combined effect of age, gender, family history (FH) and genotypes at 10 susceptibility loci that individually only modestly influence CRC risk. Risk models were generated from case-control data incorporating genotypes alone (n=39 266) and in combination with gender, age and FH (n=11 324). Model discriminatory performance was assessed using 10-fold internal cross-validation and externally using 4187 independent samples. The 10-year absolute risk was estimated by modelling genotype and FH with age- and gender-specific population risks.</p>
</sec>
<sec><st>Results</st>
<p>The median number of risk alleles was greater in cases than controls (10 vs 9, p&lt;2.2<FONT FACE="arial,helvetica">x</FONT>10<sup>&ndash;16</sup>), confirmed in external validation sets (Sweden p=1.2<FONT FACE="arial,helvetica">x</FONT>10<sup>&ndash;6</sup>, Finland p=2<FONT FACE="arial,helvetica">x</FONT>10<sup>&ndash;5</sup>). The mean per-allele increase in risk was 9% (OR 1.09; 95% CI 1.05 to 1.13). Discriminative performance was poor across the risk spectrum (area under curve for genotypes alone 0.57; area under curve for genotype/age/gender/FH 0.59). However, modelling genotype data, FH, age and gender with Scottish population data shows the practicalities of identifying a subgroup with &gt;5% predicted 10-year absolute risk.</p>
</sec>
<sec><st>Conclusion</st>
<p>Genotype data provide additional information that complements age, gender and FH as risk factors, but individualised genetic risk prediction is not currently feasible. Nonetheless, the modelling exercise suggests public health potential since it is possible to stratify the population into CRC risk categories, thereby informing targeted prevention and surveillance.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Dunlop, M. G., Tenesa, A., Farrington, S. M., Ballereau, S., Brewster, D. H., Koessler, T., Pharoah, P., Schafmayer, C., Hampe, J., Volzke, H., Chang-Claude, J., Hoffmeister, M., Brenner, H., von Holst, S., Picelli, S., Lindblom, A., Jenkins, M. A., Hopper, J. L., Casey, G., Duggan, D., Newcomb, P. A., Abuli, A., Bessa, X., Ruiz-Ponte, C., Castellvi-Bel, S., Niittymaki, I., Tuupanen, S., Karhu, A., Aaltonen, L., Zanke, B., Hudson, T., Gallinger, S., Barclay, E., Martin, L., Gorman, M., Carvajal-Carmona, L., Walther, A., Kerr, D., Lubbe, S., Broderick, P., Chandler, I., Pittman, A., Penegar, S., Campbell, H., Tomlinson, I., Houlston, R. S.]]></dc:creator>
<dc:date>2013-04-30T00:24:21-07:00</dc:date>
<dc:identifier>info:doi/10.1136/gutjnl-2011-300537</dc:identifier>
<dc:identifier>hwp:master-id:gutjnl;gutjnl-2011-300537</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Colon cancer]]></dc:subject>
<dc:title><![CDATA[Cumulative impact of common genetic variants and other risk factors on colorectal cancer risk in 42 103 individuals]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Colon</prism:section>
<prism:volume>62</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>871</prism:startingPage>
<prism:endingPage>881</prism:endingPage>
</item>
<item rdf:about="http://gut.bmj.com/cgi/content/short/62/6/882?rss=1">
<title><![CDATA[A novel myokine, secreted protein acidic and rich in cysteine (SPARC), suppresses colon tumorigenesis via regular exercise]]></title>
<link>http://gut.bmj.com/cgi/content/short/62/6/882?rss=1</link>
<description><![CDATA[
<sec><st>Objective</st>
<p>Several epidemiological studies have shown that regular exercise can prevent the onset of colon cancer, although the underlying mechanism is unclear. Myokines are secreted skeletal muscle proteins responsible for some exercise-induced health benefits including metabolic improvement and anti-inflammatory effects in organs. The purpose of this study was to identify new myokines that contribute to the prevention of colon tumorigenesis.</p>
</sec>
<sec><st>Methods</st>
<p>To identify novel secreted muscle-derived proteins, DNA microarrays were used to compare the transcriptome of muscle tissue in sedentary and exercised young and old mice. The level of circulating secreted protein acidic and rich in cysteine (SPARC) was measured in mice and humans that performed a single bout of exercise. The effect of SPARC on colon tumorigenesis was examined using SPARC-null mice. The secretion and function of SPARC was examined in culture experiments.</p>
</sec>
<sec><st>Results</st>
<p>A single bout of exercise increased the expression and secretion of SPARC in skeletal muscle in both mice and humans. In addition, in an azoxymethane-induced colon cancer mouse model, regular low-intensity exercise significantly reduced the formation of aberrant crypt foci in wild-type mice but not in SPARC-null mice. Furthermore, regular exercise enhanced apoptosis in colon mucosal cells and increased the cleaved forms of caspase-3 and caspase-8 in wild-type mice but not in SPARC-null mice. Culture experiments showed that SPARC secretion from myocytes was induced by cyclic stretch and inhibited proliferation with apoptotic effect of colon cancer cells.</p>
</sec>
<sec><st>Conclusions</st>
<p>These findings suggest that exercise stimulates SPARC secretion from muscle tissues and that SPARC inhibits colon tumorigenesis by increasing apoptosis.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Aoi, W., Naito, Y., Takagi, T., Tanimura, Y., Takanami, Y., Kawai, Y., Sakuma, K., Hang, L. P., Mizushima, K., Hirai, Y., Koyama, R., Wada, S., Higashi, A., Kokura, S., Ichikawa, H., Yoshikawa, T.]]></dc:creator>
<dc:date>2013-04-30T00:24:21-07:00</dc:date>
<dc:identifier>info:doi/10.1136/gutjnl-2011-300776</dc:identifier>
<dc:identifier>hwp:master-id:gutjnl;gutjnl-2011-300776</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Colon cancer]]></dc:subject>
<dc:title><![CDATA[A novel myokine, secreted protein acidic and rich in cysteine (SPARC), suppresses colon tumorigenesis via regular exercise]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Colon</prism:section>
<prism:volume>62</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>882</prism:startingPage>
<prism:endingPage>889</prism:endingPage>
</item>
<item rdf:about="http://gut.bmj.com/cgi/content/short/62/6/890?rss=1">
<title><![CDATA[Serotonin regulates amylase secretion and acinar cell damage during murine pancreatitis]]></title>
<link>http://gut.bmj.com/cgi/content/short/62/6/890?rss=1</link>
<description><![CDATA[
<sec><st>Objective</st>
<p>Serotonin (5-hydroxytryptamine, 5-HT) is a potent bioactive molecule involved in a variety of physiological processes. In this study, the authors analysed whether 5-HT regulates zymogen secretion in pancreatic acinar cells and the development of pancreatic inflammation, a potentially lethal disease whose pathophysiology is not completely understood.</p>
</sec>
<sec><st>Methods</st>
<p>5-HT regulation of zymogen secretion was analysed in pancreatic acini isolated from wild-type or tryptophan hydoxylase-1 knock-out (TPH1<sup>&ndash;/&ndash;</sup>) mice, which lack peripheral 5-HT, and in amylase-secreting pancreatic cell lines. Pancreatitis was induced by cerulein stimulation and biochemical and immunohistochemical methods were used to evaluate disease progression over 2&nbsp;weeks.</p>
</sec>
<sec><st>Results</st>
<p>Absence and reduced intracellular levels of 5-HT inhibited the secretion of zymogen granules both ex vivo and in vitro and altered cytoskeleton dynamics. In addition, absence of 5-HT resulted in attenuated pro-inflammatory response after induction of pancreatitis. TPH1<sup>&ndash;/&ndash;</sup> mice showed limited zymogen release, reduced expression of the pro-inflammatory chemokine MCP-1 and minimal leucocyte infiltration compared with wild-type animals. Restoration of 5-HT levels in TPH1<sup>&ndash;/&ndash;</sup> mice recovered the blunted inflammatory processes observed during acute pancreatitis. However, cellular damage, inflammatory and fibrotic processes accelerated in TPH1<sup>&ndash;/&ndash;</sup> mice during disease progression.</p>
</sec>
<sec><st>Conclusions</st>
<p>These results identify a 5-HT-mediated regulation of zymogen secretion in pancreatic acinar cells. In addition, they demonstrate that 5-HT is required for the onset but not for the progression of pancreatic inflammation. These findings provide novel insights into the normal physiology of pancreatic acinar cells and into the pathophysiology of pancreatitis, with potential therapeutic implications.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Sonda, S., Silva, A. B., Grabliauskaite, K., Saponara, E., Weber, A., Jang, J.-H., Zullig, R. A., Bain, M., Reding Graf, T., Hehl, A. B., Graf, R.]]></dc:creator>
<dc:date>2013-04-30T00:24:21-07:00</dc:date>
<dc:identifier>info:doi/10.1136/gutjnl-2011-301724</dc:identifier>
<dc:identifier>hwp:master-id:gutjnl;gutjnl-2011-301724</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Pancreas and biliary tract, Pancreatitis]]></dc:subject>
<dc:title><![CDATA[Serotonin regulates amylase secretion and acinar cell damage during murine pancreatitis]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Pancreas</prism:section>
<prism:volume>62</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>890</prism:startingPage>
<prism:endingPage>898</prism:endingPage>
</item>
<item rdf:about="http://gut.bmj.com/cgi/content/short/62/6/899?rss=1">
<title><![CDATA[Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice]]></title>
<link>http://gut.bmj.com/cgi/content/short/62/6/899?rss=1</link>
<description><![CDATA[
<sec><st>Objective</st>
<p>Cholestasis is associated with increased liver injury and morbidity after partial hepatectomy (PH), yet bile acids (BAs) are emerging as important mediators of liver regeneration. Fibroblast growth factor 15 (Fgf15, human FGF19) is a BA-induced ileum-derived enterokine that governs BA metabolism. We evaluated the relevance of Fgf15 in the preservation of BA homeostasis after PH and its potential role in the regenerative process.</p>
</sec>
<sec><st>Design</st>
<p>Liver regeneration after PH was studied in <I>Fgf15</I>  <sup>&ndash;/&ndash;</sup> and <I>Fgf15</I>  <sup>+/+</sup> mice. The effects of the BA sequestrant cholestyramine and adenovirally delivered Fgf15 were examined in this model. The role of Fgf15 in BA-induced liver growth was tested in <I>Fgf15</I>  <sup>&ndash;/&ndash;</sup> mice upon cholic acid (CA) feeding. The direct mitogenic effect of Fgf15 was evaluated in cultured mouse hepatocytes and cholangiocytes.</p>
</sec>
<sec><st>Results</st>
<p>  <I>Fgf15</I>  <sup>&ndash;/&ndash;</sup> mice showed marked liver injury and mortality after PH accompanied by persistently elevated intrahepatic BA levels. Cholestyramine feeding and adenovirally delivered Fgf15 reduced BA levels and significantly prevented this lethal outcome. Fgf15 also reduced mortality after extensive hepatectomy in <I>Fgf15<sup>+/+</sup>  </I> animals. Liver growth elicited by CA feeding was significantly diminished in <I>Fgf15</I>  <sup>&ndash;/&ndash;</sup> mice. Proliferation of hepatocytes and cholangiocytes was also noticeably reduced in CA-fed <I>Fgf15</I>  <sup>&ndash;/&ndash;</sup> mice. Fgf15 induced intracellular signalling and proliferation of cultured hepatocytes and cholangiocytes.</p>
</sec>
<sec><st>Conclusions</st>
<p>Fgf15 is necessary to maintain BA homeostasis and prevent liver injury during liver regeneration. Moreover, Fgf15 is an essential mediator of the liver growth-promoting effects of BA. Preoperative administration of this enterokine to patients undergoing liver resection might be useful to reduce damage and foster regeneration.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Uriarte, I., Fernandez-Barrena, M. G., Monte, M. J., Latasa, M. U., Chang, H. C. Y., Carotti, S., Vespasiani-Gentilucci, U., Morini, S., Vicente, E., Concepcion, A. R., Medina, J. F., Marin, J. J. G., Berasain, C., Prieto, J., Avila, M. A.]]></dc:creator>
<dc:date>2013-04-30T00:24:21-07:00</dc:date>
<dc:identifier>info:doi/10.1136/gutjnl-2012-302945</dc:identifier>
<dc:identifier>hwp:master-id:gutjnl;gutjnl-2012-302945</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Pancreas and biliary tract]]></dc:subject>
<dc:title><![CDATA[Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Hepatology</prism:section>
<prism:volume>62</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>899</prism:startingPage>
<prism:endingPage>910</prism:endingPage>
</item>
<item rdf:about="http://gut.bmj.com/cgi/content/short/62/6/911?rss=1">
<title><![CDATA[Cullin7: a new gene involved in liver carcinogenesis related to metabolic syndrome]]></title>
<link>http://gut.bmj.com/cgi/content/short/62/6/911?rss=1</link>
<description><![CDATA[
<sec><st>Background</st>
<p>Metabolic syndrome (MS) is an emerging risk factor in hepatocellular carcinoma (HCC). HCC related to MS may occur either in advanced fibrosis or before the development of cirrhosis, suggesting involvement of different molecular pathways according to the features of background liver.</p>
</sec>
<sec><st>Objective</st>
<p>To investigate genomic aberrations in HCC related to MS in order to identify new target genes involved in liver carcinogenesis.</p>
</sec>
<sec><st>Methods</st>
<p>Chromosomal aberrations of HCC obtained from 20 patients with MS (HCC/MS) were studied by comparative genomic hybridisation and compared with HCC related to hepatitis C virus (HCV) infection (HCC/HCV, n=10) and, within the group of HCC with MS, according to the condition of the background liver (presence or absence of significant fibrosis).</p>
</sec>
<sec><st>Results</st>
<p>Among the most frequent chromosomal alterations observed in HCC, 6p21.1 amplification had a higher incidence in HCC/MS than in HCC/HCV (60% vs 20%, p&lt;0.01). Advanced fibrosis/cirrhosis in the peritumoral liver was the only clinicopathological factor associated with the 6p21.1 amplicon in HCC/MS. Increased expression of cullin7 (CUL7), a gene located at the 6p21.1 locus, was demonstrated in HCC with the 6p21.1 amplicon, in parallel with a decrease in cyclin D1 expression. <I>CUL7</I> downregulation using siRNA transfection in hepatoma cell lines induced significant cyclin D1 expression (by promoting its degradation), decreased cell proliferation and increased apoptosis.</p>
</sec>
<sec><st>Conclusions</st>
<p>This study demonstrates specific genomic alterations in HCC/MS and points to <I>CUL7</I> as a novel gene potentially involved in liver carcinogenesis associated with MS, the amplification of which might influence cell proliferation.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Paradis, V., Albuquerque, M., Mebarki, M., Hernandez, L., Zalinski, S., Quentin, S., Belghiti, J., Soulier, J., Bedossa, P.]]></dc:creator>
<dc:date>2013-04-30T00:24:21-07:00</dc:date>
<dc:identifier>info:doi/10.1136/gutjnl-2012-302091</dc:identifier>
<dc:identifier>hwp:master-id:gutjnl;gutjnl-2012-302091</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Hepatic cancer]]></dc:subject>
<dc:title><![CDATA[Cullin7: a new gene involved in liver carcinogenesis related to metabolic syndrome]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Hepatology</prism:section>
<prism:volume>62</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>911</prism:startingPage>
<prism:endingPage>919</prism:endingPage>
</item>
<item rdf:about="http://gut.bmj.com/cgi/content/short/62/6/920?rss=1">
<title><![CDATA[Next generation sequencing and a new era of medicine]]></title>
<link>http://gut.bmj.com/cgi/content/short/62/6/920?rss=1</link>
<description><![CDATA[ <sec><st>Introduction</st> <p>The 10<sup>th</sup> anniversary of the publication of the first draft sequence of the human genome was celebrated recently, following the launch of the Human Genome Project in 1990.<cross-ref type="bib" refid="b1">1</cross-ref> Now, 10 years later, a human genome can be sequenced in less than 10 days and soon will be sequenced routinely within a day. This remarkable progress is due to significant advances in DNA sequencing technologies from Sanger sequencing that has been dominant for nearly 30 years to next generation sequencing (NGS, also termed massively parallel sequencing). The ability to rapidly sequence human genomes and to generate genetic, transcriptomic, epigenetic data and other genome-wide data for a relatively small cost opens up numerous opportunities for translation into the clinic over the next few years. Can the knowledge gained through NGS advances lead to personalized medicine for cancer patients? In this review we provide an overview of NGS technologies...]]></description>
<dc:creator><![CDATA[Casey, G., Conti, D., Haile, R., Duggan, D.]]></dc:creator>
<dc:date>2013-04-30T00:24:21-07:00</dc:date>
<dc:identifier>info:doi/10.1136/gutjnl-2011-301935</dc:identifier>
<dc:identifier>hwp:master-id:gutjnl;gutjnl-2011-301935</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[GUT Recent advances in basic science, Gut Education, Colon cancer]]></dc:subject>
<dc:title><![CDATA[Next generation sequencing and a new era of medicine]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Recent advances in basic science</prism:section>
<prism:volume>62</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>920</prism:startingPage>
<prism:endingPage>932</prism:endingPage>
</item>
<item rdf:about="http://gut.bmj.com/cgi/content/short/62/6/933?rss=1">
<title><![CDATA[Obesity and colorectal cancer]]></title>
<link>http://gut.bmj.com/cgi/content/short/62/6/933?rss=1</link>
<description><![CDATA[
<p>Excess body weight, as defined by the body mass index (BMI), has been associated with several diseases and includes subjects who are overweight (BMI&ge;25&ndash;29.9&nbsp;kg/m<sup>2</sup>) or obese (BMI&ge;30&nbsp;kg/m<sup>2</sup>). Overweight and obesity constitute the fifth leading risk for overall mortality, accounting for at least 2.8 million adult deaths each year. In addition around 11% of colorectal cancer (CRC) cases have been attributed to overweight and obesity in Europe. Epidemiological data suggest that obesity is associated with a 30&ndash;70% increased risk of colon cancer in men, whereas the association is less consistent in women. Similar trends exist for colorectal adenoma, although the risk appears lower. Visceral fat, or abdominal obesity, seems to be of greater concern than subcutaneous fat obesity, and any 1&nbsp;kg/m<sup>2</sup> increase in BMI confers additional risk (HR 1.03). Obesity might be associated with worse cancer outcomes, such as recurrence of the primary cancer or mortality. Several factors, including reduced sensitivity to antiangiogenic-therapeutic regimens, might explain these differences. Except for wound infection, obesity has no significant impact on surgical procedures. The underlying mechanisms linking obesity to CRC are still a matter of debate, but metabolic syndrome, insulin resistance and modifications in levels of adipocytokines seem to be of great importance. Other biological factors such as the gut microbita or bile acids are emerging. Many questions still remain unanswered: should preventive strategies specifically target obese patients? Is the risk of cancer great enough to propose prophylactic bariatric surgery in certain patients with obesity?</p>
]]></description>
<dc:creator><![CDATA[Bardou, M., Barkun, A. N., Martel, M.]]></dc:creator>
<dc:date>2013-04-30T00:24:21-07:00</dc:date>
<dc:identifier>info:doi/10.1136/gutjnl-2013-304701</dc:identifier>
<dc:identifier>hwp:master-id:gutjnl;gutjnl-2013-304701</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[GUT Recent advances in clinical practice, Colon cancer]]></dc:subject>
<dc:title><![CDATA[Obesity and colorectal cancer]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>Recent advances in clinical practice</prism:section>
<prism:volume>62</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>933</prism:startingPage>
<prism:endingPage>947</prism:endingPage>
</item>
<item rdf:about="http://gut.bmj.com/cgi/content/short/62/6/948?rss=1">
<title><![CDATA[GI highlights from the literature]]></title>
<link>http://gut.bmj.com/cgi/content/short/62/6/948?rss=1</link>
<description><![CDATA[ <sec id="s1"><st>Basic science</st><sec id="s1a"><st>Mechanistic insight into chromosomal instability in colorectal cancer</st> <p>&nbsp;<b>Burrell RA,</b> McClelland SE, Endesfelder D, <I>et al</I>. Replication stress links structural and numerical cancer chromosomal instability. <I>Nature</I> 2013;<b>494</b>:492&ndash;6.</p> <p>Chromosomal instability (CIN) results in the accumulation of numeric and structural chromosomal aberrations, and is a feature of a large proportion of colorectal cancers (CRCs). The mechanisms underlying CIN, however, remain obscure. A recent study by Burrell and colleagues has implicated replication stress as a driver of CIN in CRC. High-resolution images of anaphases of CIN positive CRC cells revealed that mitotic dysfunction was infrequent in CIN positive cells and that most chromosome segregation errors occurred through abnormal chromosome structure. The cause of these structural aberrations was postulated to be replication stress. Chemical induction of replication stress in CIN negative cells resulted in structural chromosome anomalies and segregation errors. DNA fibre assays revealed that CIN positive cell lines demonstrated...]]></description>
<dc:creator><![CDATA[McLean, M. H.]]></dc:creator>
<dc:date>2013-04-30T00:24:21-07:00</dc:date>
<dc:identifier>info:doi/10.1136/gutjnl-2013-304944</dc:identifier>
<dc:identifier>hwp:master-id:gutjnl;gutjnl-2013-304944</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[GI highlights from the literature]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>JournalScan</prism:section>
<prism:volume>62</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>948</prism:startingPage>
<prism:endingPage>949</prism:endingPage>
</item>
<item rdf:about="http://gut.bmj.com/cgi/content/short/62/6/950?rss=1">
<title><![CDATA[Does Helicobacter pylori eradication really reduce the risk of gastric cancer at the population level?]]></title>
<link>http://gut.bmj.com/cgi/content/short/62/6/950?rss=1</link>
<description><![CDATA[ <p>The development of gastric cancer is related to multiple factors, including gene, diet, environment and <I>Helicobacter pylori</I> infection. The Maastricht IV consensus stated that the eradication of <I>H pylori</I> reduces the risk of gastric cancer development.<cross-ref type="bib" refid="R1">1</cross-ref> Although the results from epidemiological and animal studies support this statement, no existing human clinical trial has resulted in the same outcome. However, <I>H pylori</I> eradication for gastric cancer prevention is still recommended in the consensus (recommendation level 1C). We believe it may be premature to put forward such a statement based on existing evidence.</p> <p>To investigate whether enough evidence exists to support <I>H pylori</I> eradication at the population level, we examined the randomised controlled clinical trials (RCTs) referenced in the consensus. The RCT conducted by Wong <I>et al</I><cross-ref type="bib" refid="R2">2</cross-ref> was one of the studies used to support the recommendation. This cohort had the longest follow-up period (7.5&nbsp;years), but the...]]></description>
<dc:creator><![CDATA[Wang, Z., Yu, Y., Yang, W., Chen, B., Li, X.]]></dc:creator>
<dc:date>2013-04-30T00:24:21-07:00</dc:date>
<dc:identifier>info:doi/10.1136/gutjnl-2012-303472</dc:identifier>
<dc:identifier>hwp:master-id:gutjnl;gutjnl-2012-303472</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[Does Helicobacter pylori eradication really reduce the risk of gastric cancer at the population level?]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>62</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>950</prism:startingPage>
<prism:endingPage>950</prism:endingPage>
</item>
<item rdf:about="http://gut.bmj.com/cgi/content/short/62/6/950-a?rss=1">
<title><![CDATA[Author's response: Helicobacter pylori eradication and gastric cancer prevention]]></title>
<link>http://gut.bmj.com/cgi/content/short/62/6/950-a?rss=1</link>
<description><![CDATA[ <p>Dr Zhu Wang and coauthors write a critical note<cross-ref type="bib" refid="R1">1</cross-ref> regarding the important issue of <I>Helicobacter</I> <I>pylori</I> eradication aiming at the prevention of gastric cancer and challenge the statement made in the Maastricht IV&ndash;Florence Consensus Report.</p> <p>The statement in the Maastricht IV&ndash;Florence Consensus Report intends to drive actions against gastric cancer by using <I>H. pylori</I> eradication as there are few beneficial alternative strategies.</p> <p>Gastric cancer is detected in most cases in advanced and non-curable stages. Screening strategies based on radiography, upper gastrointestinal endoscopy and serum pepsinogens for detection of early gastric cancer with the chance for cure have successfully been adopted so far only in Japan and Korea.<cross-ref type="bib" refid="gutjnl-2012-303564R2">2&ndash;4</cross-ref><cross-ref type="bib" refid="R3"></cross-ref><cross-ref type="bib" refid="R4"></cross-ref></p> <p>There are several arguments for adopting a screen-and-treat strategy with its potential to prevent gastric cancer.</p> <p><I>H. pylori</I> is the key trigger in the multifactorial complexity of gastric cancer based on direct and indirect...]]></description>
<dc:creator><![CDATA[Malfertheiner, P.]]></dc:creator>
<dc:date>2013-04-30T00:24:21-07:00</dc:date>
<dc:identifier>info:doi/10.1136/gutjnl-2012-303564</dc:identifier>
<dc:identifier>hwp:master-id:gutjnl;gutjnl-2012-303564</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[Author's response: Helicobacter pylori eradication and gastric cancer prevention]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>62</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>950</prism:startingPage>
<prism:endingPage>951</prism:endingPage>
</item>
<item rdf:about="http://gut.bmj.com/cgi/content/short/62/6/951?rss=1">
<title><![CDATA[Metformin and risk of hepatocellular carcinoma: are statins the missing link?]]></title>
<link>http://gut.bmj.com/cgi/content/short/62/6/951?rss=1</link>
<description><![CDATA[ <p>We read with great interest, the recent article titled &lsquo;Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies&rsquo; by Chen and colleagues published online in July in <I>Gut</I>.<cross-ref type="bib" refid="gutjnl-2012-304232R1">1</cross-ref> In this large, population-based, case-control study using the Taiwanese National Health Insurance Research Database, they reported that in patients with diabetes mellitus (DM), metformin use is associated with a decrease in the risk of hepatocellular cancer (HCC) in a dose- and duration-dependent manner. Metformin users had a 21% lower risk of HCC on multivariate stratified analysis, after adjusting for potential confounders (age, gender, hepatitis B, hepatitis C, liver cirrhosis, DM duration and antidiabetic therapy). This effect was not significant in a subset of diabetic patients with hepatitis B or hepatitis C, and in patients on thiazolidinediones, which had an independent protective effect against HCC. They appropriately acknowledged unmeasured confounders (smoking status, body mass index)...]]></description>
<dc:creator><![CDATA[Singh, S., Singh, P. P.]]></dc:creator>
<dc:date>2013-04-30T00:24:21-07:00</dc:date>
<dc:identifier>info:doi/10.1136/gutjnl-2012-304232</dc:identifier>
<dc:identifier>hwp:master-id:gutjnl;gutjnl-2012-304232</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[Metformin and risk of hepatocellular carcinoma: are statins the missing link?]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>62</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>951</prism:startingPage>
<prism:endingPage>952</prism:endingPage>
</item>
<item rdf:about="http://gut.bmj.com/cgi/content/short/62/6/952?rss=1">
<title><![CDATA[The impact of Crohn's disease genes on healthy human gut microbiota: a pilot study]]></title>
<link>http://gut.bmj.com/cgi/content/short/62/6/952?rss=1</link>
<description><![CDATA[ <p>We read with interest the paper by Rehman <I>et al</I><cross-ref type="bib" refid="gutjnl-2012-304214R1">1</cross-ref> reporting the contribution of Nod2 genotype to the composition of gut microbiota in mice and Crohn's disease (CD) patients. This was followed by a similar description for another CD-predisposing gene, FUT2.<cross-ref type="bib" refid="gutjnl-2012-304214R2">2</cross-ref> To date, 163 CD- and ulcerative colitis-risk loci have been identified, and while most of the known causative genes are involved in immune functions and response to infections, their effects on the composition of the gut microbiota are mostly unknown. Studies like those mentioned above are therefore very important, since the relative abundance of specific enteric bacteria has been clearly shown to be of pathogenetic relevance in mouse models of colitis.<cross-ref type="bib" refid="gutjnl-2012-304214R3">3</cross-ref> By studying genotype&ndash;microbiota correlations in healthy individuals, key information could also be sought for devoid of potentially confounding effects from disease status and therapeutic treatment.</p> <p>We studied the impact of 30...]]></description>
<dc:creator><![CDATA[Quince, C., Lundin, E. E., Andreasson, A. N., Greco, D., Rafter, J., Talley, N. J., Agreus, L., Andersson, A. F., Engstrand, L., D'Amato, M.]]></dc:creator>
<dc:date>2013-04-30T00:24:21-07:00</dc:date>
<dc:identifier>info:doi/10.1136/gutjnl-2012-304214</dc:identifier>
<dc:identifier>hwp:master-id:gutjnl;gutjnl-2012-304214</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[The impact of Crohn's disease genes on healthy human gut microbiota: a pilot study]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>62</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>952</prism:startingPage>
<prism:endingPage>954</prism:endingPage>
</item>
<item rdf:about="http://gut.bmj.com/cgi/content/short/62/6/952-a?rss=1">
<title><![CDATA[Authors' response: metformin and risk of hepatocellular carcinoma--a study focused on anti-diabetic agents]]></title>
<link>http://gut.bmj.com/cgi/content/short/62/6/952-a?rss=1</link>
<description><![CDATA[ <sec> <p>We thank Singh <I>et al</I><cross-ref type="bib" refid="gutjnl-2012-304319R1">1</cross-ref> for their letter<cross-ref type="bib" refid="gutjnl-2012-304319R2">2</cross-ref> commenting on our recent paper.<cross-ref type="bib" refid="gutjnl-2012-304319R3">3</cross-ref> The authors briefly summarised current evidence regarding the chemopreventive effects of statins on hepatocellular carcinoma (HCC) and noted the lack of analyses on the role of statins in HCC in our study.</p> <p>We agree that the use of statins was found to be associated with a reduced risk of HCC according to previous studies.<cross-ref type="bib" refid="gutjnl-2012-304319R3">3</cross-ref> However, not only statins but also non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, thiazolidinediones, antiviral agents, etc, were all reported to be associated with a lower risk of HCC. Sahasrabuddhe <I>et al</I> analysed the National Institutes of Health-AARP Diet and Health Study cohort and reported that aspirin users had significantly reduced risks of HCC (relative risk (RR)=0.59, 95% CI 0.45 to 0.77) and mortality (RR=0.55, 95% CI 0.45 to 0.67) due to chronic liver disease.<cross-ref...]]></description>
<dc:creator><![CDATA[Wu, C.-Y., Chen, H.-P.]]></dc:creator>
<dc:date>2013-04-30T00:24:21-07:00</dc:date>
<dc:identifier>info:doi/10.1136/gutjnl-2012-304319</dc:identifier>
<dc:identifier>hwp:master-id:gutjnl;gutjnl-2012-304319</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[Authors' response: metformin and risk of hepatocellular carcinoma--a study focused on anti-diabetic agents]]></dc:title>
<prism:publicationDate>2013-06-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>62</prism:volume>
<prism:number>6</prism:number>
<prism:startingPage>952</prism:startingPage>
<prism:endingPage>952</prism:endingPage>
</item>
</rdf:RDF>